Table 1 Participants characteristics
Breast cancer (n = 286) | p value | Prostate cancer (n = 65) | p value | |||
|---|---|---|---|---|---|---|
LMI (n = 150) | HI (n = 136) | LMI (n = 33) | HI (n = 32) | |||
Age, years | 57 ± 11 | 56 ± 11 | .349 | 70 ± 6 | 71 ± 5 | .385 |
Living situation | ||||||
Partner, n (%) | 120 (81.7) | 110 (82.7) | 29 (93.5) | 28 (90.3) | ||
Without partner, n (%) | 27 (6.5) | 23 (17.3) | 2 (6.5) | 3 (9.7) | ||
Education | .387 | .925 | ||||
University, n (%) | 100 (66.7) | 84 (61.8) | 15 (48.4) | 15 (46.9) | ||
Not University, n (%) | 50 (33.3) | 52 (38.2) | 16 (48.5) | 17 (51.5) | ||
Tobacco use | ||||||
Never, n (%) | 85 (61.1) | 76 (62.8) | .623 | 12 (40.0) | 17 (58.6) | |
Previous or less than daily use, n (%) | 44 (31.9) | 43 (35.5) | 17 (56.7) | 12 (41.4) | ||
Daily, n (%) | 9 (6.5) | 2 (1.7) | 1 (3.3) | 0 (0.0) | ||
Alcohol use, drinks/week | ||||||
Never or < 1, n (%) | 63 (42.6) | 49 (36.8) | .545 | 11 (35.5) | 6 (19.4) | .355 |
1–9, n (%) | 81 (54.7) | 81 (60.9) | 18 (58.1) | 22 (71.0) | ||
10- > 15, n (%) | 4 (2.7) | 3 (2.3) | 2 (6.5) | 3 (9.7) | ||
MVPA hrs/day | 1.17 ± 0.8 | 1.29 ± 0.8 | .327 | 1.31 ± .84 | 1.5 ± 1.08 | .452 |
VO2max ml/min/kg | 29.9 ± 7.0 | 31.25 ± 7.4 | .112 | 29.9 ± 7.4 | 30.0 ± 7.0 | .930 |
BMI | 25.3 ± 4.1 | 25.2 ± 4.4 | .849 | 27.0 ± 4.4 | 26.6 ± 3.4 | .721 |
Exercise stage resistance training (ESAI) | .008 | .810 | ||||
Not physically active, n (%) | 108 (84.4) | 83 (70.3) | 20 (76.9) | 20 (74.1) | ||
Physically active, n (%) | 20 (15.6) | 35 (29.7) | 6 (23.1) | 7 (25.9) | ||
Co-morbidities | .541 | .083 | ||||
No | 65 (46.8) | 58 (48.7) | 6 (22,2) | 10 (38.5) | ||
One co-morbidity | 38 (27.3) | 35 (29.4) | 8 (29.6) | 10 (38.5) | ||
Two co-morbidities | 26 (18.7) | 21 (17:6) | 10 (37.0) | 2 (7.7) | ||
Three or more co-morbidities | 10 (7.2) | 5 (4.2) | 3 (11.1) | 4 (15.4) | ||
Gleason Score Median (IQR) | Na | Na | 7.0 ± 1 | 7.5 ± 2 | .006 | |
= < 7, n (%) | 25 (83.3) | 16 (50.0) | ||||
> 7, n (%) | 5 (16.7) | 16 (50.0) | ||||
PSA | Na | Na | 7.0 (1) | 7.5 (2) | .420 | |
TN-classification | .375 | .294 | ||||
Tis | 7 (5.0) | 3 (2.3) | Na | Na | ||
T1-T2 | 126 (89.4) | 123 (93.9) | 25 (83.3) | 25 (80.6) | ||
T3 | 8 (5.7) | 5 (3.8) | 4 (13.3) | 2 (6.5) | ||
T4 | 0 (0.0) | 0 (0.0) | 1 (3.3) | 4 (12.9) | ||
N1 | 21 (14.8) | 23 (17.3) | 3 (9.1) | 2 (6.3) | ||
Chemotherapy n (%) | 98 (65.3) | 90 (66.8) | .813 | Na | Na | |
Capecitabine/CEX | 1 | 7 | ||||
F/E75C | 31 | 27 | ||||
F/E90-100C | 61 | 52 | ||||
Docetaxcel 100 | 53 | 41 | ||||
Docetaxcel 75–80 | 41 | 33 | ||||
Radiotherapy breast, n(%) | 122 (81.4) | 114 (84.5) | .435 | Na | Na | |
Endocrine treatment breast, n (%) | 117 (78.0) | 96 (71.1) | .324 | Na | Na | |
Radiotherapy prostate | Na | Na | ||||
Brachy therapy only, n (%) | 2 (6.1) | 0 (0.0) | ||||
External radiotherapy only, n (%) | 19 (57.6) | 13 (40.6) | ||||
Brachy therapy and external radiotherapy, n (%) | 12 (36.4) | 19 (59.4) | ||||
ADT n (%) | Na | Na | 17 (53.1) | 19 (59.4) | .614 | |